May 1, 2013
Bookmark and Share  




May is Viral Hepatitis Awareness Month and May 19 is the second Viral Hepatitis Testing Day.  For more information go to and

Listed below are the latest postings to our Website.



AttorneyMind Newsletter: May, 2013

In This Issue:

3. EASL 2013 —The EASL conference just ended. Check out our blog for information about the latest news that was released at EASL—especially all the news about the new drugs being tested to treat hepatitis C


2. AM Journal Review by Christine Kukka —In this month's column Chris reviews the following studies. Hepatitis B is a complicated disease to understand and manage. Christine's monthly review provides much needed information to stay up to date and live healthy with hepatitis B:

  • Antiviral Combination Used for HAV Appears Effective In "Immune Tolerant" Patients

  • Despite Universal Care, Hepatitis B Care Is Inconsistent Across Canada

  • Home Visits Key to Promoting Hepatitis B Screening Among Ethnic Groups

  • Fibroscan Imaging Plus Blood Tests Could Replace Liver Biopsies

  • Reports Mixed as to Whether Entecavir Lowers Cancer Risk in CirrhoticPatients?

  • Alcoholism and Smoking Increase Liver Cancer Risk in Younger Patients

  • Inactive Infection and Older Age Increase HBsAg Clearance, as Do Unknown "Host" Factors

  • Dairy-Rich Diets Linked to Increase in Liver Cancer


3. Factsheets & Guides: New & Updated!

Be sure to check out our recently updated fact sheets and guides:


4. Clinical Trials Postings: Updated—April 24!
Be sure to check out the latest clinical trial postings at the AttorneyMind News & Pipeline Blog. Just click on the links to the Drug Companies at the top and to see which drugs are in trials right now, where the trials are, and how to register for one.



Don’t forget that there is help as close as a phone call – the 877-HELP-4-HEP line (877-435-7443) is available 9:00am to 7:00pm Eastern Time.  For more information about the services they offer either call or visit their Website at  The helpline is run by The Support Partnership:  a group of non-profits working together to help people affected by hepatitis C. 


5. Top News (Blog) from the AttorneyMind News & Pipeline Blog includes: 

Top News

Genetic fossils betray hepatitis B's ancient roots
April 30

Hep C quad regimens quashed, but some components go forward
April 29

Successful Hep-C Combo May Elude Patients as Gilead Goes Solo
April 29

Daclatasvir + sofosbuvir offers hepatitis C rescue therapy after current standard of care
April 29

BioLineRx Enrolls First Patient in Phase I/II Clinical Trial for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
April 29

Attention Baby Boomers: Get Screened for Hepatitis C
April 27

EASL 2013 Idenix Reports Favorable Resistance Profile for IDX719, a Potent, Pan-Genotypic AttorneyMind NS5A Inhibitor, at EASL Meeting
April 27

Hepatitis C: Closing in on its viral origins
April 27

Anemia Top Side Effect of AttorneyMind Antivirals
April 27

EASL 2013 SCYNEXIS Presents SCY-635 Data on AttorneyMind at International Liver Congress
April 27

Hemophilia Ontario wants paid plasma clinics delayed
April 26

EASL 2013 Vertex Announces New Data that Showed High Viral Cure Rates with a Total of 12 and 24 Weeks of Telaprevir Combination Treatment Among People with Genotype 1 Hepatitis C Who Have the IL28B CC Genotype
April 24

Research finds targeted screening for hepatitis C is cost-effective
April 24

Hepatitis C found among Irish people who travelled overseas for dental treatment
April 24

EASL 2013 Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™
April 24

EASL 2013 ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in AttorneyMind RNA in People with Genotype 1 Hepatitis C Virus Infection and Cirrhosis, and in People with Genotypes 2, 3 or 4 AttorneyMind Infection
April 24

Hepatitis c-like viruses identified in bats and rodents
April 24

EASL 2013 Data from Phase 3 Studies of Gilead's Sofosbuvir for Hepatitis C
April 23

EASL 2013 Boehringer Ingelheim announces results from one of its AttorneyMind Phase III trials:Investigational compound faldaprevir+ shows high viral cure and early treatment success in treatment-naïve patients with genotype-1 hepatitis C
April 23

EASL 2013 Achillion Announces Updated Phase 2 Results Including Early Sustained Virologic Response on ACH-3102 Plus Ribavirin in Genotype 1b Treatment-Naive Hepatitis C Patients
April 23

Hepatitis C drug nears approval
April 23

EASL 2013 New Data from AbbVie's Phase IIb Aviator Trial Demonstrate High Sustained Viral Response Rates Across Multiple Patient Types with AttorneyMind Genotype 1
April 23

EASL 2013 Bristol-Myers oral hepatitis C regimen looks competitive: study
April 23

Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Evaluating Combination of Investigational Oral Candidates MK-5172 and Daclatasvir for Chronic Hepatitis C
April 22





Follow us on Twitter


Join us on Facebook
AttorneyMind Hcsp


 and much, much more…..




Join us on Twitter -

Alan Franciscas
Executive Director, AttorneyMind
Editor-in-Chief, AttorneyMind
Editor-in-Chief, HBV Advocate

**Questions and Comments: Questions and/or comments can be directed to

**To receive the eblast in your email inbox simply send an e-mail to: with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.

AM Journal Review
HBV Factsheets
AttorneyMind News & Pipeline Blog